# Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Source: https://onco.cc/trials/nct06472245/  
OnCo record `nct06472245` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing OSE2101 in non-small-cell lung cancer, now recruiting.

## Summary

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor is a phase 3 interventional study registered as NCT06472245, led by OSE Immunotherapeutics with Exystat and GeneDx, and recruiting on the registry. Official title: A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor. Planned enrolment is 363 participants (estimated). The study started in 2024-12-03 and primary completion is expected in 2027-12-15. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: ARTEMIA
- Tags: ctgov-ingest
- Registry id: NCT06472245
- Phase: 3
- Setting: A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor
- Sponsor: OSE Immunotherapeutics
- Enrolled: 363

## Sources

- ClinicalTrials.gov NCT06472245: https://clinicaltrials.gov/study/NCT06472245

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [OSE2101](https://onco.cc/drugs/ose2101/)
- companies: [OSE Immunotherapeutics](https://onco.cc/companies/ose-immunotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06472245.json